for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amgen, Inc.

AMGN.O

Latest Trade

223.46USD

Change

0.00(-0.00%)

Volume

1,934,371

Today's Range

223.14

 - 

225.95

52 Week Range

177.05

 - 

264.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
223.46
Open
225.06
Volume
1,934,371
3M AVG Volume
57.24
Today's High
225.95
Today's Low
223.14
52 Week High
264.97
52 Week Low
177.05
Shares Out (MIL)
585.69
Market Cap (MIL)
131,716.70
Forward P/E
--
Dividend (Yield %)
2.85

Next Event

Q3 2020 Amgen Inc Earnings Release

Latest Developments

More

Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib

Lilly And Amgen Announce Manufacturing Collaboration For Covid-19 Antibody Therapies

Amgen Says Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amgen, Inc.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry

Biotechnology & Drugs

Contact Info

1 Amgen Center Dr

THOUSAND OAKS, CA

91320-1730

United States

+1.805.4471000

http://www.amgen.com

Executive Leadership

Robert A. Bradway

Chairman of the Board, President, Chief Executive Officer

Peter H. Griffith

Chief Financial Officer, Executive Vice President

Murdo Gordon

Executive Vice President of Global Commercial Operations

David M. Reese

Executive Vice President - Research and Development

Esteban Santos

Executive Vice President, Operations

Key Stats

2.38 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.8K

2018

23.7K

2019

23.7K

2020(E)

25.4K
EPS (USD)

2017

12.580

2018

14.400

2019

14.820

2020(E)

15.770
Price To Earnings (TTM)
18.37
Price To Sales (TTM)
5.42
Price To Book (MRQ)
12.37
Price To Cash Flow (TTM)
12.74
Total Debt To Equity (MRQ)
321.08
LT Debt To Equity (MRQ)
320.23
Return on Investment (TTM)
14.14
Return on Equity (TTM)
11.74

Latest News

Latest News

Lilly, Amgen partner to manufacture potential COVID-19 drugs

Eli Lilly and Co has partnered with Amgen Inc to increase the supply of its experimental COVID-19 antibody treatments, a day after one of the drugs was shown to reduce the need for hospitalization.

Lilly partners with Amgen for manufacturing potential COVID-19 drugs

Eli Lilly and Co on Thursday entered into an agreement with Amgen Inc to increase the supply capacity of the drugmaker's experimental COVID-19 antibody treatments.

Amgen second-quarter revenue rises 6%, shares fall 2%

Amgen Inc said on Tuesday second-quarter revenue rose 6% as higher sales of newer drugs, including recently added psoriasis treatment Otezla, offset declining sales of older medicines which were due in some cases to people staying home to avoid exposure to the new coronavirus...

Amgen second-quarter revenue rises 6%, adjusted profit tops Street view

Amgen Inc on Tuesday reported second-quarter revenue rose 6% as higher sales of newer drugs, including recently-added psoriasis treatment Otezla, offset declining sales of older medicines.

Amgen defeats Novartis appeal over arthritis drug Enbrel's patents

A federal appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis AG's effort to void the patents.

Amgen defeats Novartis appeal over arthritis drug Enbrel's patents

A federal appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis AG's effort to void the patents.

BRIEF-Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries

* AMGEN IS SUPPORTING ADVANCEMENT OF AMG 634 FOR GLOBAL HEALTH DISEASES IN DEVELOPING COUNTRIES Source text for Eikon: Further company coverage:

Moderna names Amgen executive David Meline as CFO

Moderna Inc on Thursday named David Meline its chief financial officer, as the company develops a potential vaccine for COVID-19, the respiratory illness caused by the new coronavirus.

Moderna names Amgen executive David Meline as CFO

Moderna Inc on Thursday named David Meline its chief financial officer, as the company develops a potential vaccine for the respiratory illness caused by the new coronavirus.

BRIEF-Amgen Presents New Amg 510 Clinical Data Across Multiple Solid Tumors

* AMGEN PRESENTS NEW AMG 510 CLINICAL DATA ACROSS MULTIPLE SOLID TUMORS DURING ASCO20 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Amoy Diagnostics To Deploy Companion Diagnostic Product Tailored To Amgen's Treatment In China

* SAYS IT SIGNS AGREEMENT WITH AMGEN INC TO DEPLOY COMPANION DIAGNOSTIC PRODUCT TAILORED TO AMGEN'S LUNG CANCER TREATMENT AMG510 IN CHINA Source text in Chinese: https://bit.ly/2Zy8t45 Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Amgen Says Stockholder Proposal To Require An Independent Board Chair Was Not Approved

* AMGEN INC - EACH OF 11 NOMINEES FOR DIRECTOR WERE ELECTED TO SERVE ONE-YEAR TERM EXPIRING AT COMPANY'S 2021 ANNUAL MEETING

BRIEF-Amgen Showcases Oncology Pipeline At ASCO 2020

* AMGEN SHOWCASES ONCOLOGY PIPELINE AT ASCO 2020 Source text for Eikon: Further company coverage:

BRIEF-FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure

* FDA GRANTS FAST TRACK DESIGNATION FOR OMECAMTIV MECARBIL IN HEART FAILURE

BRIEF-Amgen Announces Positive Top-Line Results From Otezla® Phase 3 Advance Study In Mild-To-Moderate Plaque Psoriasis

* AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM OTEZLA® (APREMILAST) PHASE 3 ADVANCE STUDY IN MILD-TO-MODERATE PLAQUE PSORIASIS

BRIEF-Amgen Inc Says Kyprolis Patents Upheld Against Generic Manufacturer

* AMGEN INC - KYPROLIS (CARFILZOMIB) PATENTS UPHELD AGAINST GENERIC MANUFACTURER

BRIEF-Amgen Files For Offering Of Senior Notes

* AMGEN INC FILES FOR OFFERING OF 2.200% SENIOR NOTES DUE 2027, SENIOR NOTES DUE 2031, 3.150% SENIOR NOTES DUE 2040, 3.375% SENIOR NOTES DUE 2050 Source text: (https://bit.ly/35ur95o) Further company coverage:

Amgen studying Otezla for coronavirus, looking into other treatments

Amgen Inc <AMGN.O> on Thursday reported better-than-expected first-quarter results and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.

BRIEF-Amgen Reports First Quarter 2020 Financial Results

* REAFFIRMS FY 2020 NON-GAAP EARNINGS PER SHARE VIEW $14.85 TO $15.60

BRIEF-Amgen Inc's Q1 Total Revenue Increased 11% To $6.2 Billion

* AMGEN INC - QTRLY TOTAL REVENUE INCREASED 11% TO $6.2 BILLION; QTRLY GAAP EPS $3.07; QTRLY NON-GAAP EPS $4.17

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up